Article
Phase I/II and window-of-opportunity study of pamiparib and metronomic temozolomide for recurrent isocitrate dehydrogenase mutant gliomas.
Neuro-oncology - 1 Feb 2026
Schiff David, Ye Xiaobu, Li Jing, Ellingson Benjamin M, Wen Patrick Y, Walbert Tobias, Campian Jian, Nabors Louis B, Ozer Byram H, Desai Arati, Omuro Antonio, Desideri Serena, Danda Neeraja, Grossman Stuart, Bindra Ranjit S
Abstract excerpt
BACKGROUND: Preclinical studies demonstrate activity of poly(adenosine 5'-diphosphate-ribose) polymerase (PARP) inhibitors in isocitrate dehydrogenase (IDH) mutant gliomas. We investigated safety, tolerability, pharmacokinetics, and efficacy of the PARP inhibitor pamiparib in conjunction with metronomic low-dose temozolomide in patients with recurrent IDH mutant (IDHmt) gliomas in a multicenter Phase I/II/window...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.